Enterprise Value

7.617B

Cash

15.67B

Avg Qtr Burn

N/A

Short % of Float

4.14%

Insider Ownership

62.84%

Institutional Own.

18.55%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
COMIRNATY (BNT162b2) Details
COVID-19, Infectious disease

Approved

Quarterly sales

BNT323/DB-1303 Details
Cancer, Breast cancer

Phase 3

Data readout

BNT316 (ONC-392) Details
Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 3

Data readout

Phase 3

Initiation

Phase 2

Data readout

Phase 2

Data readout

BNT116 +/- cemiplimab Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma

Phase 2

Data readout

BNT113 Details
Head and neck cancer, Human papillomavirus

Phase 2

Data readout

BNT327/PM8002 Details
Cancer, Solid tumor/s, Cervical cancer, Platinum-resistant ovarian cancer

Phase 2

Data readout

BNT311/GEN1046 +/- pembrolizumab Details
Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 2

Data readout

Autogene cevumeran (BNT122) (RO7198457) Details
Solid tumor/s, Colorectal cancer

Phase 2

Data readout

Autogene Cevumeran (BNT122) (w/ pembrolizumab) Details
Non-small cell lung carcinoma, Solid tumor/s, Bladder cancer, Melanoma

Phase 2

Interim update

BNT324/DB-1311 Details
Solid tumor/s, Cancer

Phase 1/2

Data readout

BNT325 (DB-1305) Details
Non-small cell lung carcinoma, Cancer, Solid tumor/s, Platinum-resistant ovarian cancer

Phase 1/2

Data readout

BNT312/GEN1042 Details
Cancer, Solid tumor/s

Phase 1/2

Data readout

BNT166 Details
Vaccine, Smallpox

Phase 1/2

Data readout

BNT167 Details
Vaccine, Shingles

Phase 1/2

Update

BNT211 Details
Solid tumor/s, Cancer

Phase 1/2

Initiation

BNT327/PM8002 Details
Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 1b

Update

BNT164 Details
Vaccine, Tuberculosis

Phase 1

Data readout

BNT116 +/- cemiplimab Details
Cancer, Non-small cell lung carcinoma, Solid tumor/s

Phase 1

Data readout

BNT326/YL202 Details
Cancer, HER2-expressing cancers, Breast cancer, Non-small cell lung carcinoma

Phase 1

Data readout

Phase 1

Update